Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rejection Clear all
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Not listed No phase listed Observational

Cell-based Assays for Antibody-mediated Transplant Rejection

NCT03916822
View directory record Official record
Conditions
Antibody-Mediated Graft Rejection
Interventions
Alloantigen-specific B-cells
Diagnostic Test
Lead sponsor
Plexision
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Timeline
2019 – 2021
U.S. locations
2
States / cities
Buffalo, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Jul 23, 2026, 2:17 PM EDT
Withdrawn Early Phase 1 Interventional

Isatuximab in Lung Transplant Recipients

NCT05862766
View directory record Official record
Conditions
Antibody-mediated Rejection, Allosensitization
Interventions
Isatuximab, bone marrow biopsy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

The TOGETHER Project - Liver

NCT03874286
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
Liver Transplant
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Jul 23, 2026, 2:17 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

AlloSure Lung Assessment and Metagenomics Outcomes Study

NCT05050955
View directory record Official record
Conditions
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Not applicable Interventional

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

NCT05732779
View directory record Official record
Conditions
Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence, Health Behavior, Remote Monitoring, Patient Engagement
Interventions
DOT intervention
Other
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Coral Gables, Florida • Gainesville, Florida • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions

NCT00893542
View directory record Official record
Conditions
Prophylaxis of Organ Rejection
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Active, not recruiting No phase listed Observational

Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection

NCT04727788
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Verici Dx
Industry
Eligibility
18 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions
Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Results available

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

NCT00771745
View directory record Official record
Conditions
Renal Transplant Rejection, Transplants and Implants
Interventions
Thymoglobulin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 23, 2026, 2:17 PM EDT
Terminated Phase 1Phase 2 Interventional

Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

NCT00284531
View directory record Official record
Conditions
Cardiac Transplantation
Interventions
Daclizumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study

NCT01974999
View directory record Official record
Conditions
Kidney Disease, Kidney Failure, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

NCT00227370
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
valganciclovir, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional

IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection

NCT00351559
View directory record Official record
Conditions
Graft Rejection, Heart Diseases
Interventions
AlloMap molecular expression testing, Right ventricular endomyocardial biopsy
Device · Procedure
Lead sponsor
XDx
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

NCT02936479
View directory record Official record
Conditions
Antibody Mediated Rejection of Kidney Transplant
Interventions
C1-INH (Berinert)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 4 Interventional

Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

NCT00885820
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, MMF, Corticosteroids (Prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

NCT03707262
View directory record Official record
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

NCT00078559
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease
Interventions
Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted Conditions

NCT00894088
View directory record Official record
Conditions
Prophylaxis of Organ Rejection
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.

NCT06436027
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
Diagnostic Test
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jul 23, 2026, 2:17 PM EDT